Related Experiment Videos
Adverse reactions associated with parenteral beta agonists: serum potassium changes
1UCLA School of Medicine 90024.
New England and Regional Allergy Proceedings
|September 1, 1987
Summary
Parenteral beta-adrenergic agonists, like albuterol, can significantly lower serum potassium levels, potentially increasing arrhythmia risk. Patients on potassium-lowering drugs require careful monitoring during this treatment.
Area of Science:
- Pharmacology
- Cardiology
- Endocrinology
Background:
- Beta-adrenergic agonists are commonly used medications.
- Parenteral administration routes include intramuscular, intravenous, and subcutaneous (SC).
- Hypokalemia, or low serum potassium, is a known side effect of some medications.
Purpose of the Study:
- To investigate the hypokalemic effects of beta-adrenergic agonists administered parenterally.
- To identify patient populations at increased risk for hypokalemia.
- To highlight the potential link between hypokalemia induced by beta-agonists and adverse cardiovascular events.
Main Methods:
- Review of existing literature on beta-adrenergic agonist administration and serum potassium levels.
- Analysis of data on hypokalemia associated with specific agents like albuterol and epinephrine via parenteral routes.
- Identification of concurrent medications known to affect potassium levels.
Main Results:
- Parenteral administration of beta-adrenergic agonists, including albuterol and epinephrine, demonstrably lowers serum potassium.
- The hypokalemic effect is dose-dependent.
- Patients concurrently using corticosteroids, theophylline, diuretics, or digoxin are at higher risk.
Conclusions:
- Parenteral beta-adrenergic agonists can cause significant hypokalemia, particularly with dose escalation.
- This electrolyte imbalance may predispose patients to cardiac arrhythmias.
- Further research into the hypokalemic effects of all beta-agonists is warranted to mitigate risks, including potential contributions to asthma-related deaths.